GlassScriptPhysician profile
Kayla M Yarbrough
NPI 1407597388
$8,764.91
in general payments reported to CMS, 2019-2025
30 companies · $3,291 in 2025
The $3,291 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,067 · 2023: $1,768 · 2024: $2,639 · 2025: $3,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,377 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,377.42 |
| Education | $320.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,551.30 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,245.15 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $1,215.35 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $559.34 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $521.50 | 2023-2025 | Dupixent |
| Genzyme Corporation | $487.22 | 2022-2025 | |
| Qol Medical, LLC | $451.13 | 2022-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $349.66 | 2024-2025 | Omvoh, Zepbound |
| Madrigal Pharmaceuticals | $324.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $284.96 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $248.93 | 2022-2025 | Ibsrela |
| Celgene Corporation | $226.93 | 2022-2024 | Zeposia |
| Redhill Biopharma INC. | $180.08 | 2022-2023 | Talicia, Movantik, Aemcolo |
| Pfizer INC. | $175.07 | 2023-2025 | |
| Celltrion USA INC. | $139.59 | 2024-2025 | Vegzelma, Zymfentra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $134.04 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $92.24 | 2023-2024 | Linzess |
| Merck Sharp & Dohme LLC | $75.59 | 2022-2024 | Dificid |
| Enterra Medical, INC. | $71.35 | 2025 | |
| Evoke Pharma, INC. | $70.52 | 2022-2025 | Gimoti |
| Ipsen Biopharmaceuticals, INC | $69.26 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $65.28 | 2023-2024 | Ocaliva |
| Braintree Laboratories, INC. | $53.67 | 2023-2024 | Suflave |
| Janssen Scientific Affairs, LLC | $49.11 | 2022 | |
| Novo Nordisk INC | $34.37 | 2025 | Wegovy |
| Vivus LLC | $22.22 | 2024 | Qsymia |
| Olympus America INC. | $18.95 | 2023 | Evis Exera III Video System Center |
| Nestle Healthcare Nutrition INC. | $18.30 | 2023 | |
| Organon LLC | $15.36 | 2025 | Renflexis, Hadlima |
| Exact Sciences Corporation | $14.10 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Yarbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.